Rekod bukti kaedah

Bayesian Phase I clinical trial

A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.

Sources recorded, not reviewed

Rekod sumber

Petikan disalin secara verbatim daripada rekod sumber kaedah. Tiada pengesahan peringkat tuntutan disimpulkan daripadanya.

Bayesian Phase I Clinical Trial (Dose-Finding Design)

Rekod kaedah taksonomik · process-pipeline / epidemiology

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628
Chevret, S. (Ed.). (2006). Statistical Methods for Dose-Finding Experiments. Wiley. · ISBN 978-0470861769

Buka kaedah penuh

Tuntutan yang dikurasi

Tuntutan disimpan dalam lejar bukti, setiap satu dengan penilaiannya sendiri.

Tiada tuntutan terkurasi lagi

Pandangan ini tidak mencipta penilaian tuntutan apabila lejar tiada.

Kaedah berkaitan

Dijana daripada graf kaedah dan ditunjukkan sebagai perhubungan yang dicadangkan mesin — tiada tuntutan bukti disimpulkan.

Taxonomic bucketAdaptive Phase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketAdaptive Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketBayesian Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketDose-Response Analysismachine-suggested · Relational suggestion, not evidence.Taxonomic bucketPhase I Clinical Trialmachine-suggested · Relational suggestion, not evidence.